Hospira
4Q Revenues: $706.5 million (+9%)
4Q Earnings: $47.4 million (+78%)
FY Revenues: $2.7 billion (+2.4%)
FY Earnings: $237.7 (flat)
Comments: In the quarter, net sales to Abbott Laboratories were $38 million, up 1%, and for the year were $160.8 million, down 5%. Injectable pharmaceutical contract manufacturing revenue was $43.4 million, up 32% for the quarter, and was $183.3 million for the year, up 2.5%. In the quarter the company completed the acquisition of BresaGen Ltd., an Australia-based biotechnology company and entered an agreement to acquire Mayne Pharma Ltd. R&D expense was $55.1 million in the quarter, up 31%, and for the year was $161.6 million, up 16%.
Magazine
